Thromboprophylaxis in hip and knee arthroplasty: Are the new anticoagulants better than those previously used?;Tromboseprofylakse ved hoftefrakturkirurgi og hofte- og knæalloplastik: Er de nye antikoagulantia bedre end de hidtil anvendte?

Ugeskrift for Laeger

Volumn 167, Issue 21, 2005, Pages 2261-2265

  Nielsen, Jørn Dalsgaard ^a  

^a Klinisk Biokemisk Afdeling   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; DALTEPARIN; ENOXAPARIN; FONDAPARINUX; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; MELAGATRAN; THROMBIN INHIBITOR; WARFARIN; XIMELAGATRAN;

ANTICOAGULANT THERAPY; BLEEDING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DRUG EFFICACY; DRUG HALF LIFE; HIP ARTHROPLASTY; HUMAN; KNEE ARTHROPLASTY; LUNG EMBOLISM; MAJOR CLINICAL STUDY; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; SURGICAL PATIENT; THROMBOSIS; THROMBOSIS PREVENTION; TOTAL HIP PROSTHESIS; TOTAL KNEE REPLACEMENT; TREATMENT OUTCOME; VENOUS THROMBOEMBOLISM;

ANTICOAGULANTS; ARTHROPLASTY, REPLACEMENT, HIP; ARTHROPLASTY, REPLACEMENT, KNEE; AZETIDINES; BENZYLAMINES; CLINICAL TRIALS, PHASE III; FIBRINOLYTIC AGENTS; GLYCINE; HUMANS; POLYSACCHARIDES; POSTOPERATIVE COMPLICATIONS; PULMONARY EMBOLISM; THROMBOEMBOLISM; VENOUS THROMBOSIS;

EID: 20444416035     PISSN: 00415782     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (21)

1. Nordstrom M, Lindblad B, Bergqvist D et al. A prospective study of the incidence of deep-vein thrombosis within a defined urban population J Intern Med 1992;232:155-60.
2. Heit JA, O'Fallon WM, Petterson TM et al. Relative impact of risk factors for deep vein thrombosis and pulmonary embolism: a population-based study. Arch Intern Med 2002;162:1245-8
3. Geerts WH, Heit JA, Clagett GP et al. Prevention of venous thromboembolism. Chest 2001;119(suppl 1):132S-175S.
4. White RH, Gettner S, Newman JM et al. Predictors of rehospitalization for symptomatic venous thromboembolism after total hip arthroplasty. N Engl J Med 2000;343:1758-64.
5. Cosmi B, Legnani C, Cini M et al. Thrombophilia and residual vein thrombosis are independent risk factors for recurrent venous thromboembolism. J Thromb Haemost 2003;(suppl 1)1: abstract OC150.
6. Hull RD, Pineo GF, Stein PD et al. extended out-of-hospital low-molecular-weight heparin prophylaxis against deep venous thrombosis in patients after elective hip arthroplasty: a systematic review. Ann Intern Med 2001;135:858-69.
7. Eriksson BI, Bauer KA, Lassen MR et al. Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after hip-fracture surgery. N Engl J Med 2001;345:1298-304.
8. Bauer KA, Eriksson BI, Lassen MR et al. Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after elective major knee surgery. N Engl J Med 2001;345:1305-10.
9. Lassen MR, Bauer KA, Eriksson BI et al. Postoperative fondaparinux versus preoperative enoxaparin for prevention of venous thromboembolism in elective hip replacement surgery: a randomised double-blind comparison. Lancet 2002;359:1715-20.
10. Turpie AGG, Bauer KA, Eriksson BI et al. Postoperative fondaparinux versus postoperative enoxaparin for prevention of venous thromboembolism after elective hipreplacement surgery: a randomised double-blind trial. Lancet 2002;359:1721-6.
11. White RH, Romano PS, Zhou H. Incidence and time course of thromboembolic outcome following total hip or knee arthroplasty. Arch Intern Med 1998;158:1525-31.
12. Eriksson BI. Improvements in the prevention of postoperative venous thromboembolism in hip fracture patients. Orthopedics. 2003;26(suppl 8):851-8.
13. Gustafsson D, Elg M. The pharmacodynamics and pharmacokinetics of the oral direct thrombin inhibitor ximelagatran and its active metabolite melagatran: a mini-review. Thromb Res 2003;109:S9-S15.
14. Eriksson BI. Clinical experience of melagatran/ximelagatran in major orthopaedic surgery. Thromb Res 2003;109:S23-S9.
15. Eriksson BI, Agnelli G, Cohen AT et al. The direct thrombin inhibitor melagatran followed by oral ximelagatran compared with enoxaparin for the prevention of venous thromboembolism after total hip or knee replacement: the EXPRESS study. J Thromb Haemost 2003;1:2490-6.
16. Francis CW, Berkowitz SD, Comp PC et al. Comparison of ximelagatran with warfarin for the prevention of venous thromboembolism after total knee replacement. N Engl J Med 2003;349:1703-12.
17. Colwell CW, Berkowitz SD, Comp PC et al. Randomized, double-blind comparison of ximelagatran, an oral direct thrombin inhibitor, and warfarin to prevent venous thromboembolism (VTE) after total knee replacement (TKA): EXULT B. Blood 2003;102: abstract 39.
18. Raskob GE, Hirsh J. Controversies in the timing of the first dose of anticoagulant prophylaxis against venous thromboembolism after major ortopedic surgery. Chest 2003;124(suppl):379-85.
19. Hull R, Pineo G, Francis C et al. Low-molecular-weight heparin prophylaxis using dalteparin in close proximity to surgery vs warfarin in hip arthroplasty patients: a double blind, randomized comparison: North American Fragmin Trial Investigators. Arch Intern Med 2000;160:2199-2207.
20. Horlocker TT, Wedel DJ, Benzon H et al. Regional anesthesia in the anticoagulated patient: defining the risks (The second ASRA consensus conference on neuraxial anesthesia and anticoagulation). Reg Anesth Pain Med 2003;28:172-97.
21. Gundgaard J, Olsen J. Cost effectiveness of fondaparinux compared to enoxaparin as venous thromboembolism prophylaxis in Denmark. Rapport fra Center for anvendt sundhedstjenesteforskning og Teknologivurdering. Syddansk Universitet, 2003.